Merck (MRK) stock tumbles as slowing China sales for its HPV prevention drug, Gardisil, weigh on the company's outlook. PepsiCo (PEP) shares are under pressure following a cautious forecast due to ...
Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...
In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback